14.2.2 Secondary endpoints

Table 14.2.2.10.3: Comparison of cumulative incidence of relapse at 3 years after start of investigational treatment between SCT and ContRuxo - Full Analysis Population

Timepoint	Treatment arm	Cumulative incidence Function Estimate, CIF	Standard Error	Absolute difference in CIF	95% Lower confidence interval for absolute difference	95% Upper confidence interval for absolute difference	Z-value	P-value
3 years	ContRuxo	0.563	0.154	0.381	0.061	0.701	2.335	0.02
	SCT	0.183	0.053					

CIF: Cumulative incidence function. ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic stem cell transplantation.
3 years defined as 3 years + 92 days after the date of inclusion to allow for Ruxolitinib induction period. All numerical values are rounded to 3 decimal places.

Page 1 of 1